Overview:

Summary

Medical equipment report, “AutoGenomics and PGXL Laboratories to Partner to Expand Molecular Testing in Pharmacogenetics” provides key insights on the deal. The report provides analysis and impact on the global in-vitro diagnostics market as a result of the deal. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Deal overview of the partnership between AutoGenomics and PGXL Laboratories.
- Strategic rationale behind the deal including analysis on the impact of the deal on the industry and on both the companies.
- Company profiles of AutoGenomics and PGXL Laboratories.

Reasons to buy

- Understand the business strategy behind the deal involving the pioneer of pharmacogenetic testing.
- Explore possible repercussions on the market dynamics of in-vitro medical equipment industry.

1 Table of Contents 1
2 Summary 1
3 AutoGenomics and PGXL Laboratories to Partner to Expand Molecular Testing in Pharmacogenetics 1
3.1 Deal Overview 1
3.2 Strategic Rationale 2
3.2.1 Improved Workflow for PGXL Laboratories 2
3.2.2 Developing Superior Tests by Leveraging Intellectual Capital 2
4 Company Profiles 2
4.1 AutoGenomics, Inc. 2
4.1.1 Overview 2
4.2 PGXL Laboratories 2
4.2.1 Overview 2
5 Appendix 2
5.1 Research Methodology 3
5.2 Secondary Research 3
5.3 Primary Research 3
5.4 Models 3
5.5 Forecasts 4
5.6 Expert Panels 4
5.7 GlobalData Consulting 4
5.8 Contact Us 4
5.9 Disclaimer 4